CA Patent

CA3227324A1 — Treatment of serotonin reuptake inhibitor withdrawal syndrome

Assigned to Individual · Expires 2023-01-12 · 3y expired

What this patent protects

The present invention relates to a method of treating serotonin reuptake inhibitor withdrawal syndrome comprising the administration of a therapeutically effective amount of escitalopram gentisate.

USPTO Abstract

The present invention relates to a method of treating serotonin reuptake inhibitor withdrawal syndrome comprising the administration of a therapeutically effective amount of escitalopram gentisate.

Drugs covered by this patent

Patent Metadata

Patent number
CA3227324A1
Jurisdiction
CA
Classification
—
Expires
2023-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.